PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 6, 2026Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics1 citations

Melatonin in Integrative Oncology: Biological Mechanisms, Therapeutic Evidence and Implementation Strategies

JNJarosław NuszkiewiczJWJoanna WróblewskaMJMarek Jóźwiak

Key Points

  • This review aims to summarize the biological mechanisms and therapeutic evidence of melatonin in integrative oncology.
  • Narrative review synthesizing molecular, experimental, and clinical data on melatonin.
  • Analysis of melatonin's biological actions, including redox-regulatory and immune modulation functions.
  • Investigation of synergistic effects with chemotherapy, radiotherapy, and other treatment modalities.
  • Melatonin shows promise in reducing treatment toxicity and improving tumor control.
  • Preclinical evidence supports its role in enhancing cancer therapy outcomes and quality of life.
  • Implementation of melatonin faces challenges in standardization and clinician awareness.

Abstract

Melatonin, an endogenous indoleamine primarily synthesized in the pineal gland, has emerged as a promising adjunctive agent within integrative oncology due to its pleiotropic biological actions. Beyond its well-known chronobiological functions, melatonin exerts potent redox-regulatory, anti-inflammatory, oncostatic, and immune-modulating effects that are relevant across multiple stages of carcinogenesis and cancer therapy. Oxidative stress (OS), defined as an imbalance between reactive oxygen and nitrogen species (ROS/RNS) generation and antioxidant defenses, plays a central role in DNA damage, protein adduct formation, and lipid peroxidation, ultimately contributing to mutation accumulation, treatment resistance, and tumor progression. Melatonin modulates these OS-related processes through both receptor-dependent and receptor-independent mechanisms, including mitochondrial stabilization, enhancement of antioxidant enzyme activity, inhibition of pro-oxidant pathways, regulation of cell-cycle checkpoints, and promotion of apoptosis in malignant cells while protecting healthy tissues. Preclinical studies demonstrate synergistic interactions between melatonin and chemotherapy, radiotherapy, targeted agents, and immunotherapies, with consistent reductions in treatment toxicity and improvements in tumor control. Emerging clinical evidence supports its potential benefits in quality of life, sleep regulation, fatigue, and selected oncologic outcomes, although heterogeneity in dosing, formulations, and study design remains a key limitation. At the organizational and system levels, successful integration of melatonin into oncology practice requires interdisciplinary collaboration, standardized protocols, clinician awareness, regulatory clarity, and evidence-based implementation strategies. The aim of this narrative review is to synthesize current molecular, experimental, and clinical evidence on melatonin in integrative oncology, with particular emphasis on redox-related mechanisms, therapeutic interactions, and implementation challenges.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Nuszkiewicz et al. (2026) studied this question.

synapsesocial.com/papers/69aa70b8531e4c4a9ff5ab9bhttps://doi.org/10.32604/or.2026.077020
Ask AI
Helpful
Bookmark
Share
View Full Paper